We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0R1B market cap is 40.23B. The company's latest EPS is USD 8.0132 and P/E is 24.26.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 14.44B | 13.62B | 11.03B | 10.17B | 9.84B |
| Operating Income | 7.04B | 4.55B | 3.09B | 2.76B | 2.03B |
| Net Income | 5.89B | 4B | 1.81B | 3.05B | 1.16B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 27.23B | 24.62B | 23.88B | 24.55B | 26.84B |
| Total Liabilities | 13.9B | 13.93B | 12.92B | 11.17B | 12.05B |
| Total Equity | 13.34B | 10.69B | 10.96B | 13.39B | 14.8B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 7.08B | 4.23B | 3.64B | 1.38B | 1.55B |
| Investing | 470.5M | -608.6M | -563.7M | 1.58B | -4.1B |
| Financing | -5.86B | -5.27B | -2.09B | -1.75B | 149.3M |
| Market Cap | 40.23B |
| Price to Earnings Ratio | 24.26 |
| Price to Sales Ratio | 2.86 |
| Price to Cash Ratio | 26.83 |
| Price to Book Ratio | 1.9 |
| Dividend Yield | - |
| Shares Outstanding | 144.9M |
| Average Volume (1 week) | 1.12k |
| Average Volume (1 Month) | 1.4k |
| 52 Week Change | 0.00% |
| 52 Week High | 277.67 |
| 52 Week Low | 277.67 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Biogen Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.biogen.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
